Protara Therapeutics

Contributing Author

Recent Articles by Protara Therapeutics

May-18	Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 TARA -9.80% GlobeNewswire
May-15	Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naive Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC TARA GlobeNewswire
May-13	Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update TARA GlobeNewswire
Apr-27	Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients at the American Urological Association Annual Meeting TARA GlobeNewswire
Mar-10	Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update TARA GlobeNewswire
Feb-23	TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer TARA -26.38% TARA +8.63% GlobeNewswire
Feb-19	Protara Therapeutics to Participate in Upcoming Investor Conferences TARA +7.20% GlobeNewswire
Feb-02	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TARA GlobeNewswire
Jan-22	Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium TARA GlobeNewswire
Jan-12	Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones TARA -8.87% GlobeNewswire
Jan-07	Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference TARA +11.13% GlobeNewswire
Jan-07	Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support TARA +11.13% GlobeNewswire
Jan-05	Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations TARA GlobeNewswire
Dec-08	Protara Announces Closing of $75 Million Public Offering TARA GlobeNewswire
Dec-04	Protara Announces Pricing of $75 Million Public Offering TARA -18.78% GlobeNewswire
Dec-04	Protara Announces Proposed Public Offering TARA -18.78% TARA GlobeNewswire
Dec-03	Protara Therapeutics Announces Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients TARA +9.32% GlobeNewswire
Dec-01	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients on Wednesday, December 3, 2025 TARA -8.67% TARA -7.72% GlobeNewswire
Nov-19	Protara Therapeutics Announces Positive Interim Results Demonstrating Robust Responses in the Ongoing Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations TARA GlobeNewswire
Nov-18	Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations on Wednesday, November 19, 2025 TARA +21.18% GlobeNewswire
Nov-17	Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naive NMIBC Patients at the 26th Annual Meeting of the Society of Urologic Oncology TARA GlobeNewswire
Nov-10	Protara Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update TARA +5.59% GlobeNewswire
Nov-04	Protara Therapeutics Named a 2026 Best Places to Work Winner by BioSpace TARA -9.28% GlobeNewswire
Oct-01	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TARA GlobeNewswire
Sep-02	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TARA GlobeNewswire
Aug-27	Protara Therapeutics to Participate in Upcoming Investor Conferences TARA GlobeNewswire
Aug-11	Protara Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update TARA GlobeNewswire
Aug-01	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TARA GlobeNewswire
Jul-01	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TARA -7.59% GlobeNewswire
Jun-30	Protara Therapeutics Announces Addition to the Russell 3000 Index TARA +5.21% GlobeNewswire
Jun-02	Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer TARA +8.55% GlobeNewswire
May-13	Protara Therapeutics to Participate in Upcoming Investor Conferences TARA GlobeNewswire
May-08	Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update TARA GlobeNewswire
May-01	Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TARA GlobeNewswire

Protara Therapeutics

Recent Articles by Protara Therapeutics

Upgrade your Finviz experience